光化性角化病治疗中场癌化处理的重要性
光化性角化病(AK)是长期紫外线暴露皮肤中的角质形成细胞非典型增生,可见病灶周围亚临床日光损伤区存在相同遗传改变,称为场癌化。病灶导向治疗不能处理场癌化且复发率高,而场导向治疗(如ingenol mebutate、imiquimod、双氯芬酸)可清除可见和亚临床AK病灶并减少新病灶。指南已认识到治疗场癌化的重要性,需将指南转化为临床实践并加强医患教育。
要点
- 可见AK病灶周围亚临床日光损伤区存在相同遗传改变,即场癌化。
- 病灶导向治疗不能处理场癌化,可能导致高复发率。
- 场导向治疗可清除可见和亚临床AK病灶并减少新病灶。
核心结论
- AK治疗应重视场癌化的处理,场导向治疗可清除可见和亚临床病灶并减少新病灶。
主要发现
- 可见AK病灶周围的亚临床日光损伤区含有与病灶相同的遗传改变,称为场癌化。
- AK病灶和场癌化与包括侵袭性鳞状细胞癌在内的皮肤癌风险增加相关。
- 病灶导向治疗虽能清除可见AK,但不处理场癌化,可导致高复发率。
- 场导向治疗如ingenol mebutate、imiquimod和双氯芬酸可清除可见和亚临床AK病灶并减少治疗区域内新病灶的发生。
- 临床前研究提示场导向治疗可能预防或延缓非黑色素瘤皮肤癌的复发。
临床怎么用
- AK治疗指南现已认识到对AK患者治疗场癌化的重要性,有必要将治疗指南适配到临床实践中。
- 需要对医生和患者进行关于未治疗场癌化后果的教育,以减轻AK相关负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Actinic keratoses (AKs) are intraepithelial atypical proliferations of keratinocytes that develop in skin that has undergone long-term exposure to ultraviolet radiation. Given the ageing population and an increasing prevalence of AK, the socio-economic burden of AK is likely to rise over the coming years. Areas of subclinical (non-visible) sun damage in the periphery of visible AK lesions contain the same genetic changes as those found in the lesions themselves, and are known as areas of field cancerization. AK lesions and the field are associated with an increased risk of skin cancer, including invasive squamous cell carcinoma. Although effective in clearing visible AK, lesion-directed therapies do not address field cancerization and can lead to high recurrence rates. In contrast, field-directed therapies, such as ingenol mebutate, imiquimod and diclofenac, can clear both visible and subclinical AK lesions and reduce the development of new lesions in the treated field. Additionally, preclinical studies suggest that field therapy may prevent or delay the recurrence of non-melanoma skin cancer. AK treatment guidelines now recognize the importance of treating the field in patients with AK, and adaptation of treatment guidelines into clinical practice is warranted. Physician and patient education around the consequences of leaving the field of cancerization untreated is necessary in order to reduce the increasing burden associated with AK.
引用
- Stockfleth E. The importance of treating the field in actinic keratosis. J Eur Acad Dermatol Venereol. 2017. PMID: 28263021. doi:10.1111/jdv.14092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。